Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in KIT-Positive Acral and Mucosal Melanoma
NCT00700882Phase 2Completed
- Sponsor
- Eastern Cooperative Oncology Group
- Start
- Jul 2009
- Primary completion
- May 2016
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in acral lentiginous melanoma (ALM), mucosal melanoma, melanoma, sponsored by Eastern Cooperative Oncology Group. Started Jul 2009; status: completed.
02
Drugs
dasatinib
03
Conditions
acral lentiginous melanoma (ALM)mucosal melanomamelanoma
Beyond the preview
Go deeper on NCT00700882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00700882.